Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−3.55 EUR
−50.13 M EUR
0.00 EUR
6.81 M
About Elicio Therapeutics, Inc.
Sector
Industry
CEO
Robert T. Connelly
Website
Headquarters
Boston
Founded
2011
ISIN
US28657F1030
FIGI
BBG013JXMGK7
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cancer immunotherapies. It focuses on its Amphiphile platform for trafficking lymph nodes. The company was founded by Darrell Irvine in August 2011 and is headquartered in Boston, MA.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 9HA is 9.35 EUR — it hasn't changed in the past 24 hours. Watch Elicio Therapeutics, Inc stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange Elicio Therapeutics, Inc stocks are traded under the ticker 9HA.
9HA stock has risen by 124.76% compared to the previous week, the month change is a 124.76% rise, over the last year Elicio Therapeutics, Inc has showed a 124.76% increase.
We've gathered analysts' opinions on Elicio Therapeutics, Inc future price: according to them, 9HA price has a max estimate of 15.18 EUR and a min estimate of 10.96 EUR. Watch 9HA chart and read a more detailed Elicio Therapeutics, Inc stock forecast: see what analysts think of Elicio Therapeutics, Inc and suggest that you do with its stocks.
9HA stock is 2.19% volatile and has beta coefficient of 0.85. Track Elicio Therapeutics, Inc stock price on the chart and check out the list of the most volatile stocks — is Elicio Therapeutics, Inc there?
Yes, you can track Elicio Therapeutics, Inc financials in yearly and quarterly reports right on TradingView.
Elicio Therapeutics, Inc is going to release the next earnings report on Nov 6, 2025. Keep track of upcoming events with our Earnings Calendar.
9HA earnings for the last quarter are −0.56 EUR per share, whereas the estimation was −0.58 EUR resulting in a 3.65% surprise. The estimated earnings for the next quarter are −0.47 EUR per share. See more details about Elicio Therapeutics, Inc earnings.
Elicio Therapeutics, Inc revenue for the last quarter amounts to 0.00 EUR, matching the estimated figure, and no changes in revenue are expected for the next quarter.
9HA net income for the last quarter is −8.97 M EUR, while the quarter before that showed −10.36 M EUR of net income which accounts for 13.47% change. Track more Elicio Therapeutics, Inc financial stats to get the full picture.
No, 9HA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 27, 2025, the company has 32 employees. See our rating of the largest employees — is Elicio Therapeutics, Inc on this list?
Like other stocks, 9HA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Elicio Therapeutics, Inc stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Elicio Therapeutics, Inc technincal analysis shows the strong buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Elicio Therapeutics, Inc stock shows the strong buy signal. See more of Elicio Therapeutics, Inc technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.